GE HealthCare announces first patient dosed in Phase 2/3 LUMINA trial for manganese-based MRI contrast agent under FDA Fast Track designation ...
Zacks Investment Research on MSN
GEHC moves manganese-based MRI contrast agent into phase 2/3 trial
GE HealthCare Technologies Inc. GEHC recently announced that the first patient has been dosed in its Phase 2/3 LUMINA ...
GE HealthCare Technologies (NasdaqGS:GEHC) has dosed the first patient in its global LUMINA Phase 2/3 trial of mangaciclanol, ...
Mangaciclanol’s Phase I trial showed it was well tolerated, with no serious adverse events or clinically significant findings ...
This Collection invites original research articles on phase contrast imaging, looking at the latest technological developments and the use of this technique in original applications. Phase contrast ...
GE HealthCare doses first patient in phase 2/3 LUMINA trial for manganese-based MRI contrast agent, mangaciclanol: Chalfont St Giles,?UK Saturday, April 25, 2026, 12:00 Hrs [IST] ...
Techniques that exploit the phase of X-rays, not just their absorption, have the potential to transform X-ray imaging in hospitals, reports Jude Dineley Improved imaging Marian Willner from the ...
Figure 1： The flowchart of ACDPC iterative reconstruction joint optimization algorithm. (a) ACDPC imaging system based on half-annular illumination. (b) Three annular illumination patterns and their ...
BERLIN--(BUSINESS WIRE)--Bayer, a global leader in radiology, today announced positive topline results of the pivotal Phase III QUANTI studies evaluating the efficacy and safety of gadoquatrane, an ...
Researchers all over Germany have developed a new system for X-ray imaging, which is suited for both living specimens and sensitive materials. The system records images of micrometer resolution at a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results